Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia

Alice Cani, Carolina Simioni, Alberto M. Martelli, Giorgio Zauli, Giovanna Tabellini, Simona Ultimo, James A. McCubrey, Silvano Capitani, Luca M. Neri

Research output: Contribution to journalArticle

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder in which chemotherapy resistance and refractory relapses occur, with a poorer prognostic outcome.Constitutively active PI3K/Akt/mTOR pathway is a common feature of T-ALL upregulating cell proliferation, survival and drug resistance. This pathway is currently under clinical trials with small molecules inhibitors (SMI).To verify whether a multi-inhibition treatment against Akt protein could enhance the efficacy of individual drug administration and overcome drug resistance as well as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines the effects of combined treatments with three Akt inhibitors with different mode of action, GSK690693, MK-2206 and Perifosine.In cells with hyperactivated Akt, combined administration of the drugs displayed a significant synergistic and cytotoxic effect and affected PI3K/Akt/mTOR pathway at much lower concentration than single drug use. Highest synergistic effect for full inhibition of Akt was also related to the timing of every drug administration. Furthermore the triple treatment had greater efficacy in inducing cell cycle arrest in G0/G1 phase and both apoptosis and autophagy.Targeting Akt as a key protein of PI3K/Akt/mTOR pathway with multiple drugs might represent a new and promising pharmacological strategy for treatment of T-ALL patients.

Original languageEnglish
Pages (from-to)6597-610
Number of pages14
JournalOncotarget
Volume6
Issue number9
DOIs
Publication statusPublished - Mar 30 2015

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Phosphatidylinositol 3-Kinases
Pharmaceutical Preparations
Drug Resistance
Therapeutics
Cell Cycle Resting Phase
Autophagy
G1 Phase
Cell Cycle Checkpoints
Cell Survival
Proteins
Cell Proliferation
Clinical Trials
Pharmacology
Apoptosis
Recurrence
Drug Therapy
Cell Line

Keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Apoptosis
  • Autophagy
  • Cell Cycle Checkpoints
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Enzyme Activation
  • Heterocyclic Compounds, 3-Ring
  • Humans
  • Jurkat Cells
  • Molecular Targeted Therapy
  • Oxadiazoles
  • Phosphatidylinositol 3-Kinase
  • Phosphorylation
  • Phosphorylcholine
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-akt
  • Signal Transduction
  • TOR Serine-Threonine Kinases
  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

Cani, A., Simioni, C., Martelli, A. M., Zauli, G., Tabellini, G., Ultimo, S., ... Neri, L. M. (2015). Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget, 6(9), 6597-610. https://doi.org/10.18632/oncotarget.3260

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. / Cani, Alice; Simioni, Carolina; Martelli, Alberto M.; Zauli, Giorgio; Tabellini, Giovanna; Ultimo, Simona; McCubrey, James A.; Capitani, Silvano; Neri, Luca M.

In: Oncotarget, Vol. 6, No. 9, 30.03.2015, p. 6597-610.

Research output: Contribution to journalArticle

Cani, A, Simioni, C, Martelli, AM, Zauli, G, Tabellini, G, Ultimo, S, McCubrey, JA, Capitani, S & Neri, LM 2015, 'Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia', Oncotarget, vol. 6, no. 9, pp. 6597-610. https://doi.org/10.18632/oncotarget.3260
Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S et al. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget. 2015 Mar 30;6(9):6597-610. https://doi.org/10.18632/oncotarget.3260
Cani, Alice ; Simioni, Carolina ; Martelli, Alberto M. ; Zauli, Giorgio ; Tabellini, Giovanna ; Ultimo, Simona ; McCubrey, James A. ; Capitani, Silvano ; Neri, Luca M. / Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. In: Oncotarget. 2015 ; Vol. 6, No. 9. pp. 6597-610.
@article{79ad67a6fbe846a993acfca676cd1039,
title = "Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia",
abstract = "T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder in which chemotherapy resistance and refractory relapses occur, with a poorer prognostic outcome.Constitutively active PI3K/Akt/mTOR pathway is a common feature of T-ALL upregulating cell proliferation, survival and drug resistance. This pathway is currently under clinical trials with small molecules inhibitors (SMI).To verify whether a multi-inhibition treatment against Akt protein could enhance the efficacy of individual drug administration and overcome drug resistance as well as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines the effects of combined treatments with three Akt inhibitors with different mode of action, GSK690693, MK-2206 and Perifosine.In cells with hyperactivated Akt, combined administration of the drugs displayed a significant synergistic and cytotoxic effect and affected PI3K/Akt/mTOR pathway at much lower concentration than single drug use. Highest synergistic effect for full inhibition of Akt was also related to the timing of every drug administration. Furthermore the triple treatment had greater efficacy in inducing cell cycle arrest in G0/G1 phase and both apoptosis and autophagy.Targeting Akt as a key protein of PI3K/Akt/mTOR pathway with multiple drugs might represent a new and promising pharmacological strategy for treatment of T-ALL patients.",
keywords = "Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Autophagy, Cell Cycle Checkpoints, Dose-Response Relationship, Drug, Drug Synergism, Enzyme Activation, Heterocyclic Compounds, 3-Ring, Humans, Jurkat Cells, Molecular Targeted Therapy, Oxadiazoles, Phosphatidylinositol 3-Kinase, Phosphorylation, Phosphorylcholine, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Signal Transduction, TOR Serine-Threonine Kinases, Journal Article, Research Support, Non-U.S. Gov't",
author = "Alice Cani and Carolina Simioni and Martelli, {Alberto M.} and Giorgio Zauli and Giovanna Tabellini and Simona Ultimo and McCubrey, {James A.} and Silvano Capitani and Neri, {Luca M.}",
year = "2015",
month = "3",
day = "30",
doi = "10.18632/oncotarget.3260",
language = "English",
volume = "6",
pages = "6597--610",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "9",

}

TY - JOUR

T1 - Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia

AU - Cani, Alice

AU - Simioni, Carolina

AU - Martelli, Alberto M.

AU - Zauli, Giorgio

AU - Tabellini, Giovanna

AU - Ultimo, Simona

AU - McCubrey, James A.

AU - Capitani, Silvano

AU - Neri, Luca M.

PY - 2015/3/30

Y1 - 2015/3/30

N2 - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder in which chemotherapy resistance and refractory relapses occur, with a poorer prognostic outcome.Constitutively active PI3K/Akt/mTOR pathway is a common feature of T-ALL upregulating cell proliferation, survival and drug resistance. This pathway is currently under clinical trials with small molecules inhibitors (SMI).To verify whether a multi-inhibition treatment against Akt protein could enhance the efficacy of individual drug administration and overcome drug resistance as well as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines the effects of combined treatments with three Akt inhibitors with different mode of action, GSK690693, MK-2206 and Perifosine.In cells with hyperactivated Akt, combined administration of the drugs displayed a significant synergistic and cytotoxic effect and affected PI3K/Akt/mTOR pathway at much lower concentration than single drug use. Highest synergistic effect for full inhibition of Akt was also related to the timing of every drug administration. Furthermore the triple treatment had greater efficacy in inducing cell cycle arrest in G0/G1 phase and both apoptosis and autophagy.Targeting Akt as a key protein of PI3K/Akt/mTOR pathway with multiple drugs might represent a new and promising pharmacological strategy for treatment of T-ALL patients.

AB - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder in which chemotherapy resistance and refractory relapses occur, with a poorer prognostic outcome.Constitutively active PI3K/Akt/mTOR pathway is a common feature of T-ALL upregulating cell proliferation, survival and drug resistance. This pathway is currently under clinical trials with small molecules inhibitors (SMI).To verify whether a multi-inhibition treatment against Akt protein could enhance the efficacy of individual drug administration and overcome drug resistance as well as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines the effects of combined treatments with three Akt inhibitors with different mode of action, GSK690693, MK-2206 and Perifosine.In cells with hyperactivated Akt, combined administration of the drugs displayed a significant synergistic and cytotoxic effect and affected PI3K/Akt/mTOR pathway at much lower concentration than single drug use. Highest synergistic effect for full inhibition of Akt was also related to the timing of every drug administration. Furthermore the triple treatment had greater efficacy in inducing cell cycle arrest in G0/G1 phase and both apoptosis and autophagy.Targeting Akt as a key protein of PI3K/Akt/mTOR pathway with multiple drugs might represent a new and promising pharmacological strategy for treatment of T-ALL patients.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Apoptosis

KW - Autophagy

KW - Cell Cycle Checkpoints

KW - Dose-Response Relationship, Drug

KW - Drug Synergism

KW - Enzyme Activation

KW - Heterocyclic Compounds, 3-Ring

KW - Humans

KW - Jurkat Cells

KW - Molecular Targeted Therapy

KW - Oxadiazoles

KW - Phosphatidylinositol 3-Kinase

KW - Phosphorylation

KW - Phosphorylcholine

KW - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

KW - Protein Kinase Inhibitors

KW - Proto-Oncogene Proteins c-akt

KW - Signal Transduction

KW - TOR Serine-Threonine Kinases

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.18632/oncotarget.3260

DO - 10.18632/oncotarget.3260

M3 - Article

C2 - 25788264

VL - 6

SP - 6597

EP - 6610

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 9

ER -